Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in the ATTR-CM trial. The patient was hospitalized, is being closely monitored and is undergoing treatment, according to the biotech.

Another major investment by ARK was the acquisition of 385,585 shares of Block Inc (NYSE:XYZ), a financial services and mobile payment company formerly known as Square, with a total value of $30,669,430. This trade was distributed across three ETFs: ARKK, ARKW, and ARKF, indicating a diversified interest in the fintech space.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ongoing R&D and commercialization plans. Investors should note the binary risk of clinical outcomes and regulatory hurdles,

6 analysts have expressed a variety of opinions on Intellia Therapeutics (NASDAQ:NTLA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best performers on Monday. Intellia Therapeutics soared to a new all-time high on Monday,

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at JMP Securities in a research note issued on Friday,Benzinga reports. NTLA has been the subject of a number of other reports.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z. ・The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.